FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2173598215> ?p ?o ?g. }

• W2173598215 endingPage "e0141253" @default.
• W2173598215 startingPage "e0141253" @default.
• W2173598215 abstract "Muscle invasive bladder cancer (MIBC, stage ≥T2) is generally associated with poor prognosis, constituting the second most common cause of death among genitourinary tumours. Due to high molecular heterogeneity significant variations in the natural history and disease outcome have been observed. This has also delayed the introduction of personalized therapeutics, making advanced stage bladder cancer almost an orphan disease in terms of treatment. Altered protein glycosylation translated by the expression of the sialyl-Tn antigen (STn) and its precursor Tn as well as the activation of the PI3K/Akt/mTOR pathway are cancer-associated events that may hold potential for patient stratification and guided therapy. Therefore, a retrospective design, 96 bladder tumours of different stages (Ta, T1-T4) was screened for STn and phosphorylated forms of Akt (pAkt), mTOR (pmTOR), S6 (pS6) and PTEN, related with the activation of the PI3K/Akt/mTOR pathway. In our series the expression of Tn was residual and was not linked to stage or outcome, while STn was statically higher in MIBC when compared to non-muscle invasive tumours (p = 0.001) and associated decreased cancer-specific survival (log rank p = 0.024). Conversely, PI3K/Akt/mTOR pathway intermediates showed an equal distribution between non-muscle invasive bladder cancer (NMIBC) and MIBC and did not associate with cancer-specif survival (CSS) in any of these groups. However, the overexpression of pAKT, pmTOR and/or pS6 allowed discriminating STn-positive advanced stage bladder tumours facing worst CSS (p = 0.027). Furthermore, multivariate Cox regression analysis revealed that overexpression of PI3K/Akt/mTOR pathway proteins in STn+ MIBC was independently associated with approximately 6-fold risk of death by cancer (p = 0.039). Mice bearing advanced stage chemically-induced bladder tumours mimicking the histological and molecular nature of human tumours were then administrated with mTOR-pathway inhibitor sirolimus (rapamycin). This decreased the number of invasive lesions and, concomitantly, the expression of STn and also pS6, the downstream effector of the PI3K/Akt/mTOR pathway. In conclusion, STn was found to be marker of poor prognosis in bladder cancer and, in combination with PI3K/Akt/mTOR pathway evaluation, holds potential to improve the stratification of stage disease. Animal experiments suggest that mTOR pathway inhibition could be a potential therapeutic approach for this specific subtype of MIBC." @default.
• W2173598215 created "2016-06-24" @default.
• W2173598215 creator A5005096269 @default.
• W2173598215 creator A5008483447 @default.
• W2173598215 creator A5009837639 @default.
• W2173598215 creator A5012254846 @default.
• W2173598215 creator A5023561928 @default.
• W2173598215 creator A5025251077 @default.
• W2173598215 creator A5035096310 @default.
• W2173598215 creator A5038178239 @default.
• W2173598215 creator A5052493209 @default.
• W2173598215 creator A5058331288 @default.
• W2173598215 creator A5067808731 @default.
• W2173598215 creator A5073487168 @default.
• W2173598215 creator A5077185285 @default.
• W2173598215 creator A5084173639 @default.
• W2173598215 creator A5089331319 @default.
• W2173598215 date "2015-11-16" @default.
• W2173598215 modified "2023-10-07" @default.
• W2173598215 title "Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics" @default.
• W2173598215 cites W1626592142 @default.
• W2173598215 cites W1925873373 @default.
• W2173598215 cites W1966197897 @default.
• W2173598215 cites W1966757146 @default.
• W2173598215 cites W1969668456 @default.
• W2173598215 cites W1973607027 @default.
• W2173598215 cites W1993747943 @default.
• W2173598215 cites W2012295573 @default.
• W2173598215 cites W2013627997 @default.
• W2173598215 cites W2015353103 @default.
• W2173598215 cites W2015891741 @default.
• W2173598215 cites W2017181626 @default.
• W2173598215 cites W2017569895 @default.
• W2173598215 cites W2028691804 @default.
• W2173598215 cites W2042064148 @default.
• W2173598215 cites W2062216281 @default.
• W2173598215 cites W2068201818 @default.
• W2173598215 cites W2072697288 @default.
• W2173598215 cites W2075150946 @default.
• W2173598215 cites W2076975629 @default.
• W2173598215 cites W2105452584 @default.
• W2173598215 cites W2110812842 @default.
• W2173598215 cites W2111709677 @default.
• W2173598215 cites W2116215875 @default.
• W2173598215 cites W2117295753 @default.
• W2173598215 cites W2128613144 @default.
• W2173598215 cites W2131344205 @default.
• W2173598215 cites W2133249643 @default.
• W2173598215 cites W2138003468 @default.
• W2173598215 cites W2145936343 @default.
• W2173598215 cites W2151781453 @default.
• W2173598215 cites W2153956724 @default.
• W2173598215 cites W2158065853 @default.
• W2173598215 cites W2164142083 @default.
• W2173598215 cites W2164361945 @default.
• W2173598215 cites W224280792 @default.
• W2173598215 cites W2425945762 @default.
• W2173598215 cites W4294214970 @default.
• W2173598215 cites W81098990 @default.
• W2173598215 cites W983246850 @default.
• W2173598215 doi "https://doi.org/10.1371/journal.pone.0141253" @default.
• W2173598215 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4646664" @default.
• W2173598215 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26569621" @default.
• W2173598215 hasPublicationYear "2015" @default.
• W2173598215 type Work @default.
• W2173598215 sameAs 2173598215 @default.
• W2173598215 citedByCount "60" @default.
• W2173598215 countsByYear W21735982152016 @default.
• W2173598215 countsByYear W21735982152017 @default.
• W2173598215 countsByYear W21735982152018 @default.
• W2173598215 countsByYear W21735982152019 @default.
• W2173598215 countsByYear W21735982152020 @default.
• W2173598215 countsByYear W21735982152021 @default.
• W2173598215 countsByYear W21735982152022 @default.
• W2173598215 countsByYear W21735982152023 @default.
• W2173598215 crossrefType "journal-article" @default.
• W2173598215 hasAuthorship W2173598215A5005096269 @default.
• W2173598215 hasAuthorship W2173598215A5008483447 @default.
• W2173598215 hasAuthorship W2173598215A5009837639 @default.
• W2173598215 hasAuthorship W2173598215A5012254846 @default.
• W2173598215 hasAuthorship W2173598215A5023561928 @default.
• W2173598215 hasAuthorship W2173598215A5025251077 @default.
• W2173598215 hasAuthorship W2173598215A5035096310 @default.
• W2173598215 hasAuthorship W2173598215A5038178239 @default.
• W2173598215 hasAuthorship W2173598215A5052493209 @default.
• W2173598215 hasAuthorship W2173598215A5058331288 @default.
• W2173598215 hasAuthorship W2173598215A5067808731 @default.
• W2173598215 hasAuthorship W2173598215A5073487168 @default.
• W2173598215 hasAuthorship W2173598215A5077185285 @default.
• W2173598215 hasAuthorship W2173598215A5084173639 @default.
• W2173598215 hasAuthorship W2173598215A5089331319 @default.
• W2173598215 hasBestOaLocation W21735982151 @default.
• W2173598215 hasConcept C11960822 @default.
• W2173598215 hasConcept C121608353 @default.
• W2173598215 hasConcept C126322002 @default.
• W2173598215 hasConcept C143998085 @default.
• W2173598215 hasConcept C2777609662 @default.
• W2173598215 hasConcept C2780352672 @default.

• next